Vir Biotechnolog Rg
VIR
USD
STOCK MARKET:
NMS
Closed
 
...
Large gap with delayed quotes
Last quote
12/27/2024 - 17:20:00
Bid
12/27/2024 - 15:59:59
Bid
Volume
Ask
12/27/2024 - 15:59:59
Ask
Volume
7.465
+0.065 ( +0.88% )
7.47
400
7.48
15,500
More information
Analysis by TheScreener
24.12.2024
Evaluation Negativ  
Interest None  
Sensibility High  
Analysis date: 24.12.2024
Global Evaluation
  Negativ
The stock is classified in the negative zone since 15.11.2024.
Interest
  None
No interest since 24.12.2024.
Earnings Rev Trend
  -0.10
 
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is negative since 22.11.2024 at a price of 7.12.
Evaluation
  Strongly overvalued
 
Based on its growth potential and our own criteria, at its current price the stock is strongly overvalued.
MT Tech Trend
  Negative
 
The forty day Medium Term Technical Trend is negative since 13.12.2024. The confirmed Technical Reverse point (Tech Reverse + 1.75%) is .
4wk Rel Perf
  -1.69%
 
The four week relative underperformance versus SP500 is 1.69%.
Sensibility
  High
The stock has been on the high-sensitivity level since 15.11.2024.
Bear Market Factor
  High
On average, the stock has a tendency to amplify the drops in the index by 0.74%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 5.15%.
Mkt Cap in $bn
  1.01
With a market capitalization <$2bn, VIR BIOTECHNOLOGY is considered a small-cap stock.
G/PE Ratio
  0.28
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
  -2.09
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
  0.58%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
  8
Over the last seven weeks, an average of 8 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  109
For 1% of index variation, the stock varies on average by 1.09%.
Correlation
  0.22
Stock movements are strongly independent of index variations.
Value at Risk
  3.07
The value at risk is estimated at USD 3.07. The risk is therefore 41.55%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  11.09.2020